Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT05812027 is registered in ClinicalTrials.gov with TScan Therapeutics, Inc. as lead sponsor.

NCT NCT05812027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05812027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Lead sponsor
TScan Therapeutics, Inc.
Phase
Observational
Overall status
Active, not recruiting
Start date
June 26, 2023
Completion date
January 14, 2027
Enrollment
1,150 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, head and neck cancer, hpv16 related cancers, non small cell lung cancer, nut carcinoma, sarcoma, uveal melanoma